# A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

> **NCT04913285** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 400 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Non-small Cell Lung Cancer
- Melanoma

## Interventions

- **DRUG:** KIN-2787
- **DRUG:** KIN-2787 and binimetinib

## Key facts

- **NCT ID:** NCT04913285
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-04
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913285, "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04913285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*